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Introduction 97
Tobacco smoking is an established cause of bladder and kidney cancer (50% and 20% of 98 incident cases, respectively [1] ). For people who smoke, there are clear benefits of quitting. 99
For people who don't smoke, or would never have started smoking in the absence of EC, 100 there are potential risks. As such, it is important for urologists and urological health 101 researchers to understand the possible implications of EC use in urology patients.[2] 102 103
What are e-cigarettes? 104
Electronic cigarettes (ECs) are battery-powered devices that all work by heating a liquid ('e-105 liquid') to create an aerosol that is then inhaled. The aerosol produced is more commonly 106 referred to as vapour, and the use of the device as 'vaping'. Some are designed to resemble 107 traditional cigarettes ('cigalikes' or first generation products), whereas newer generation 108 (tank systems) are modular and can be personalised. The cigalike devices are closed systems 109 and are, generally, not refillable. They may be made for single use (i.e. disposable) or they 110
can have a rechargeable battery and replaceable cartridges that contain the heating coil (or 111 atomizer) and liquid. The newer generation products are generally greater in size and 112 consist of a high capacity lithium battery, sometimes with variable power, an atomizer, and 113 a tank that the user fills with liquid. The atomizer is usually manually activated, which gives 114 greater control over vapour production than the automated systems. Most people start out 115 using a cigalike device, but regular vapers generally use tank system ECs [3] . 116 117 There are three main components of the e-liquid; propylene glycol or glycerol or a mix of 118 these, nicotine, and flavouring. The propylene glycol/glycerol mix is important for user 119 satisfaction (e.g. a high propylene glycol content gives a greater 'throat hit'), but may also 120 6 be important for nicotine delivery. [4] Nicotine concentrations vary from 0 to 36mg/ml, with 121 18mg/ml being the most commonly used. [5, 6] However the European Tobacco Products 122 Directive, which came into effect on 20 May 2016, now limits the concentration to a 123 maximum of 20mg/ml. The directive also restricts the volume of bottles of e-liquid to 10ml 124 and volume of EC tanks to 2ml, as well as a number of other measures including restrictions 125 on advertising and promotions and packaging and labelling requirements. EC liquid (e-liquid) 126 is available in numerous flavours, which are important for user satisfaction. In Great Britain, 127 the most commonly used flavour by current vapers is tobacco, followed by fruit and 128 mint/menthol flavours.
[3] The flavours used are considered safe for oral ingestion, but the 129 effects of heating these and then inhaling them are unknown. Some flavours appear to be 130 more cytotoxic than others (e.g. strawberry [7] and cinnamon [8]) and associated with 131 7 North American and European countries. For example, the prevalence of ever-use among 145 individuals aged ≥15 years in 27 states of the European Union increased from 7.2% in 2012 146 to 11.9% in 2014 (Table 1) 
Evidence acquisition 208
In order to identify any eligible trials addressing EC use and urological health outcomes, a search of 209 the electronic databases MEDLINE was carried out from inception to August 2016. MEDLINE search 10 authors. Given that EC use and urological outcomes is an emerging clinical issue with a fragmentary 216 evidence base and involves rapidly evolving technologies, a narrative synthesis of these data was 217 undertaken. [30] 218 219 3. Evidence synthesis 220
Current urological health outcomes and trials of EC use 221
We found no published clinical studies, which are a priori designed to evaluate the impact of 222
ECs on urological health outcomes. We were able to find only one published protocol for a 223 prospective observational study that will document hospitalizations and adverse events that 224 could report urological health outcomes (although not specifically designed to do this). ECs are thought to be much safer for long-term health by the public than traditional tobacco 235 cigarettes.
[37] It is however, important to recognise that these devices are not entirely 236 benign. Due to the nature and components of these devices, ECs 
Prospective cohort studies 296
Five studies, with long-term outcomes, have looked at the use of ECs in people who were 297 not ready to quit smoking. One followed 40 smokers over two years and reported that 13% 298 achieved at least six months of CO validated abstinence from conventional cigarettes and 299 28% had achieved a sustained ≥50% reduction from baseline cigarette consumption.[56, 57] 300
The second tested the same approach with 14 smokers with schizophrenia and reported 301 Although there are data to support ECs as a potential aid to smoking cessation in the 319 general population, it is important to note that in those already diagnosed with cancer, 320 there is less certainty. Prospective cohort data from a major US cancer treatment centre 321
reported that significantly higher percentage of EC users were highly nicotine dependent 322 when compared with nonusers and were twice as likely to be smoking at the time of follow-323 up as nonusers.
[63] 324 325
Randomised controlled trials 326
To date only three randomised controlled trials that have examined the effects of EC in 327 helping people stop smoking have been published. One examined their use in people who 328 wanted to quit,[64] and two in those who did not.[65, 66] In a study of people who wanted 329 to quit from New Zealand [64], the investigators compared nicotine-containing ECs (n=289), 330 with 21mg nicotine patches (n=295), and with non-nicotine ECs (placebo ECs, n=73). 331
Participants were provided with a referral to telephone quitline but with no face-to-face 332 contact. In this minimal support context, there were no significant differences in validated 333 continuous abstinence at six months (7.3% nicotine EC, 5.8% nicotine patch, and 4.1% non-334 nicotine EC). These findings were similar to an Italian study comparing EC use (two different 335 doses for 12 weeks) to non-nicotine ECs in 300 smokers who were not intending to quit.
[65] 336
Biochemically validated six-month abstinence rates (at one-year follow-up) were not 337 significantly different; 13%, 9% and 4% in the three groups, respectively. Both of these 338 pioneering trials were underpowered and used first generation EC products with poor 339 nicotine delivery. These ECs often malfunctioned and neither is now available on the 340 market. 
European health policy and ECs 374
The use of ECs for smoking reduction or cessation is influenced by a range of factors that 375 extend beyond the safety and efficacy of these devices. Regulation also affects their use, in 376 particular policies that may result in changes to the price, availability or promotion of the 377 products.
[73] The global context for EC regulation is highly variable.
[74] In many countries 378 such as Argentina, Brazil, Indonesia, and Singapore, the import, distribution and sale of ECs 379 is banned. Other countries such as New Zealand, South Africa and Switzerland have 380 implemented a two tier system where ECs themselves and nicotine-free cartridges or e-381 liquid can be sold sale of but nicotine-containing refills or e-liquid are prohibited. Other 382 countries permit their import and sale but certain restrictions on age of sale or marketing 383 are in place. Policies have evolved as use has become more prevalent and governments 384 have responded to a range of concerns often about youth uptake, addictiveness or safety. 385
Ironically, many jurisdictions now have more restrictive regulation on ECs than tobacco 386
products. 387
In the European Union (EU), EC use is prevalent and countries have taken a range of 388 approaches to regulation. and importers of ECs to comply with a notification process that involves providing data on: 394 ingredients and emissions; nicotine delivery and uptake; health and addictive effects; the 395 product components and production process; and a declaration on safety and quality when 396 used as intended. It is anticipated that this process will remove some products from the 397 market that can't meet these requirements. 398
399
The TPD also places a limit on nicotine concentration with devices that do not have a 400 medicinal license limited to 20mg/ml and refill containers up to a maximum volume of 10ml. 401
The basis for this requirement is contested and some concerns have been expressed about 402 this limit in terms of delivering nicotine to smokers who are highly dependent.
[77] ECs must 403 also be secure in terms of leakage and breakage, be child and tamper proof and contain a 404 leaflet with warnings, instructions and further information. Packaging must contain a 405 warning label about nicotine being a highly addictive substance and promotional elements 406 on packaging are also subject to regulation. Some forms of marketing are also restricted 407 under the TPD including the prohibition of all cross border advertising and sponsorship 408 although other forms of marketing such as billboards and point of sale are at the discretion 409 of member states. Finally, annual submissions on products are required to be submitted to 410 governments and a system for collecting information on adverse effects on health must be 411 in place. Other policy issues such as age of sale, use in public places and the regulation of 412 flavours are the responsibility of national governments. 413 414
Discussion 415
We were not able to find any clinical studies with prospective outcomes assessing EC use 416 and urological outcomes. We have presented data around toxicology of compounds found 417 in EC constituents and how this might impact urological health, but these must be viewed as 418 hypothesis generating and treated with caution. As such the use and potential outcomes 419 associated with EC use in urological patient populations is still to be determined. Some * Prevalences for individual countries are also presented in the article. 478 ** Those who responded "daily or less than daily" to the question "Do you currently use e-479 cigarettes on a daily basis, less than daily, or not at all?" 480 ∫ Males were 2.5-times more likely to be monthly or more users than females. 481 ¶ Among those with no current tobacco smoking .  482  483  484  485  486  487  488  489  490  491  492  493  494  495  496  497  498  499  500  501  502 
